Illumina Inc (ILMN) 177.14 $ILMN
Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Illumina, Inc. (NASDAQ: ILMN) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Sep 09, 9:11AM CDT
What:
Quiet Stocks Are Typical In Market Right Now
at Investor's Business Daily - Mon Sep 08, 5:18PM CDT
Quiet volume has been the chief characteristic of the stock market in recent weeks. The last time either the Nasdaq or the S&P 500 showed above-average volume for the week was in the week ended Aug. 1. Many leaders in the Big Cap 20 are also keeping...
Why Illumina (ILMN) Stock Is Gaining Today
at The Street - Mon Sep 08, 9:56AM CDT
Illumina (ILMN) shares are up after having coverage initiated with an 'equal weight' rating by analysts at Morgan Stanley (MS) on Monday.
Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions
Business Wire - Mon Sep 08, 5:30AM CDT
--Consortium Will Recommend Standards for Applying Next-Generation Sequencing to Cancer Tumors
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Alexion Pharmaceuticals' Soliris Wins NICE Backing for aHUS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:00PM CDT
Alexion's (ALXN) Soliris is highly effective for treating aHUS as per NICE.
3 Stocks Advancing The Health Care Sector
at The Street - Thu Sep 04, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
SmarTrend Watching for Potential Rebound in Shares of Illumina After 1.08% Loss
Comtex SmarTrend(R) - Wed Sep 03, 3:51PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $177.29 to a high of $181.96. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $178.03 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Illumina Falls 1.08% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Sep 03, 3:50PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $177.29 to a high of $181.96. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $178.03 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
Why Google Wants to Map Your Body With Its Baseline Study
Leo Sun, The Motley Fool - Motley Fool - Sun Aug 31, 11:02AM CDT
Google is a company built on providing information to make our lives easier. While that information included search histories, maps, and cloud-based software in the past, the search giant recently launched a new Google X project to better...
Insider Trading Alert - ILMN, ENS And RL Traded By Insiders
at The Street - Fri Aug 29, 10:15AM CDT
Stocks with insider trader activity include ILMN, ENS and RL
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Illumina, Inc. (NASDAQ: ILMN) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Sep 09, 9:11AM CDT
What:
Quiet Stocks Are Typical In Market Right Now
at Investor's Business Daily - Mon Sep 08, 5:18PM CDT
Quiet volume has been the chief characteristic of the stock market in recent weeks. The last time either the Nasdaq or the S&P 500 showed above-average volume for the week was in the week ended Aug. 1. Many leaders in the Big Cap 20 are also keeping...
Why Illumina (ILMN) Stock Is Gaining Today
at The Street - Mon Sep 08, 9:56AM CDT
Illumina (ILMN) shares are up after having coverage initiated with an 'equal weight' rating by analysts at Morgan Stanley (MS) on Monday.
Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions
Business Wire - Mon Sep 08, 5:30AM CDT
--Consortium Will Recommend Standards for Applying Next-Generation Sequencing to Cancer Tumors
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Alexion Pharmaceuticals' Soliris Wins NICE Backing for aHUS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:00PM CDT
Alexion's (ALXN) Soliris is highly effective for treating aHUS as per NICE.
3 Stocks Advancing The Health Care Sector
at The Street - Thu Sep 04, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
SmarTrend Watching for Potential Rebound in Shares of Illumina After 1.08% Loss
Comtex SmarTrend(R) - Wed Sep 03, 3:51PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $177.29 to a high of $181.96. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $178.03 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Illumina Falls 1.08% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Sep 03, 3:50PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $177.29 to a high of $181.96. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $178.03 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
Why Google Wants to Map Your Body With Its Baseline Study
Leo Sun, The Motley Fool - Motley Fool - Sun Aug 31, 11:02AM CDT
Google is a company built on providing information to make our lives easier. While that information included search histories, maps, and cloud-based software in the past, the search giant recently launched a new Google X project to better...
Insider Trading Alert - ILMN, ENS And RL Traded By Insiders
at The Street - Fri Aug 29, 10:15AM CDT
Stocks with insider trader activity include ILMN, ENS and RL
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery 
